Mohamed H. Zaki - Concepedia

Author

Mohamed H. Zaki

Dana-Farber Cancer Institute

Also Known As

M .ZAKI, M H Zaki, M. H. Zaki, M. Zaki, MOHAMED H. ZAKI, Mohamed H Zaki, Mohamed H. Zaki, Mohamed Zaki, Mohamed zaki

120

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Hackensack University Medical Center Vancouver General Hospital Institut Català d'Oncologia National and Kapodistrian University of Athens

About

Mohamed H. Zaki is an author at Dana-Farber Cancer Institute specializing in medicine, pharmacotherapy, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	1.8K
2	Health Sciences	9	9	1.3K
3	Cell Biology	4	4	288
4	Engineering	1	1	15
5	Public Health	1	1	27

Mohamed H. Zaki

Publications

3.4K

Citations

H-Index

Page 1

	Year	Citations
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Jesús F. San Miguel, Katja Weisel, Philippe Moreau, The Lancet Oncology Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy	2013	794
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study Paul G. Richardson, David S. Siegel, Ravi Vij, Blood	2014	380
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial Paul G. Richardson, Albert Oriol, Meral Beksaç, The Lancet Oncology Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy	2019	375
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma Meletios Α. Dimopoulos, Antonio Palumbo, Paolo Corradini, Blood	2016	162
Inhibition of Interleukin-6 with CNTO328, an Anti-Interleukin-6 Monoclonal Antibody, Inhibits Conversion of Androgen-Dependent Prostate Cancer to an Androgen-Independent Phenotype in Orchiectomized Mice Lauren P. Wallner, Jinlu Dai, June Escara‐Wilke, Cancer Research	2006	146
<i>Chlamydia</i> <i>pneumoniae</i> Inhibits Apoptosis in Human Peripheral Blood Mononuclear Cells Through Induction of IL-10 Yuemei Geng, Ryan Shane, Klára Berencsi, The Journal of Immunology	2000	130
Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma Peter M. Voorhees, Qing Chen, Deborah J. Kuhn, Clinical Cancer Research	2007	115
CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude mice Mohamed H. Zaki, Jeffrey A. Nemeth, Mohit Trikha International Journal of Cancer ImmunologyCell DeathImmunologic MechanismImmunotherapyIl-6 Function	2004	114
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1 Ilaria T. Cavarretta, Hannes Neuwirt, Gerold Untergasser, Oncogene Il-6 Autocrine LoopCellular ModelImmunologyCell DeathImmune Checkpoint Inhibitor	2006	102
Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines Maria Wysocka, Mohamed H. Zaki, Lars E. French, Blood	2002	76

Page 1